Verrica Pharmaceuticals reports Q2 adjusted EPS (21c), consensus (21c)

Reports Q2 revenue $182,000, consensus $70k. “The U.S Food and Drug Administration approval of YCANTH for the treatment of molluscum marks the most important achievement in our company’s history” said Ted White, Verrica’s President and Chief Executive Officer. “With no other FDA-approved therapies available prior to YCANTH, molluscum represents one of the largest and most underserved patient populations in all of dermatology, and we could not be prouder to launch this product that can positively impact so many patients. Following the approval of YCANTH, we had the opportunity to secure significant, non-dilutive capital to ensure that we have ample resources to support the YCANTH product launch. With our cash runway extended into the first quarter of 2025, and our commercial organization fully operational, we are ready to make YCANTH available to the millions of patients who will benefit from this therapy.”